Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

Winship Cancer Institute, Emory University, Atlanta, GA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Atlanta, GA
Treatments:Biologic therapyHospital:Winship Cancer Institute, Emory University
Drugs:Journal:Link
Date:Sep 2012

Description:

Patients:
This phase 2 study involved advanced non-small-cell lung cancer patients who were divided into two separate treatment groups. Group A consisted of 94 patients with a median age of 60 years; 55 were male. Group B had 94 patients with a median age of 62 years; 56 were male.

Treatment:
Patients in group A were treated with the biologic therapy agent called dacomitinib, which is a tyrosine kinase inhibitor that interferes with tumor growth.

Patients in group B were treated with the biologic therapy agent called erlotinib, which is a tyrosine kinase inhibitor that interferes with tumor growth.

Toxicities:
Treatment-related death due to pneumonia was reported for group A. Grade 3 diarrhea and grade 1-3 skin disorders were also reported.

Treatment-related deaths due to pneumonia and pulmonary embolism were reported for group B. Grade 3 acne and diarrhea, and grade nausea and fatigue were also reported.

Results:
The median overall survival rates for groups A and B were 9.53 and 7.44 months, respectively.

Support:
This study was supported by the Pfizer pharmaceutical company.

Correspondence: Dr. Suresh S. Ramalingam; email: [email protected]



Back